Onfasprodil

A pharmaceutical compound

Onfasprodil
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Onfasprodil is a pharmaceutical compound that acts as a selective NMDA receptor antagonist. It is primarily researched for its potential therapeutic effects in neurological conditions such as stroke, traumatic brain injury, and certain types of chronic pain.

Mechanism of Action

Onfasprodil functions by selectively inhibiting the NMDA receptor, a type of glutamate receptor in the central nervous system. The NMDA receptor plays a crucial role in synaptic plasticity, memory, and learning. By modulating this receptor, Onfasprodil can potentially reduce excitotoxicity, a process where excessive glutamate activity leads to neuronal damage and cell death.

Pharmacokinetics

The pharmacokinetic profile of Onfasprodil includes its absorption, distribution, metabolism, and excretion. It is typically administered orally, and its bioavailability is influenced by factors such as the presence of food and the pH of the gastrointestinal tract. Onfasprodil is metabolized in the liver and excreted primarily through the kidneys.

Therapeutic Applications

Onfasprodil is being investigated for several therapeutic applications:

• Stroke: By reducing excitotoxicity, Onfasprodil may help protect neurons during ischemic events.
• Traumatic Brain Injury: It may mitigate secondary brain damage following trauma.
• Chronic Pain: Onfasprodil's modulation of NMDA receptors may help alleviate certain types of chronic pain, particularly those resistant to conventional analgesics.

Side Effects

Potential side effects of Onfasprodil include dizziness, nausea, and headaches. As with other NMDA receptor antagonists, there is a risk of neuropsychiatric effects, such as hallucinations or cognitive disturbances, especially at higher doses.

Research and Development

Research on Onfasprodil is ongoing, with several clinical trials aimed at evaluating its efficacy and safety in various neurological conditions. The compound's development is part of a broader effort to find effective treatments for conditions involving excitotoxicity and neurodegeneration.

Related pages

• NMDA receptor antagonist
• Glutamate receptor
• Neuroprotection
• Excitotoxicity